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High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is considered the standard of care for
multiple myeloma patients who are eligible for transplantation. The process of autografting comprises the following steps: control
of the primary disease by using a certain induction therapeutic protocol, mobilization of stem cells, collection of mobilized stem
cells by apheresis, cryopreservation of the apheresis product, administration of high-dose pretransplant conditioning therapy,
and ﬁnally infusion of the cryopreserved stem cells after thawing. However, in cancer centers that treat patients with multiple
myeloma and have transplantation capabilities but lack or are in the process of acquiring cryopreservation facilities, alternatively
noncryopreserved autologous stem cell therapy has been performed with remarkable success as the pretransplant conditioning
therapy is usually brief.
1.Introduction
Multiple myeloma (MM) accounts for 1% of all cancers
and about 10% of all hematologic malignancies [1]. It is
characterized by neoplastic proliferation of a clone of plasma
cells producing a monoclonal immunoglobulin and can
present as a single lesion (plasmacytoma) or multiple lesions
(MM). Clonal plasma cells proliferate in the bone marrow
and can cause extensive lytic bony lesions, osteopenia, and
pathological fractures [2]. MM is a heterogenous disease
rather than a single disease entity, as some patients progress
rapidly despite therapy, whilst others may not require active
therapy for a number of years [2].
OncethediagnosisofMMismade,thepatientundergoes
staging evaluation in order to start an appropriate line
of therapy. The international staging system (ISS) divides
patients into 3 categories according to serum albumin
and beta-2-microglobulin levels. Conventional cytogenetics,
ﬂuorescence in situ hybridization (FISH), and molecular
studies help to stratify patients into standard-risk, high-risk,
and ultra-high-risk groups to determine prognosis and to
reﬁne management of patients. Gene expression proﬁling
and plasma cell labeling index can identify high-risk groups
and select the most appropriate novel therapies to be used
[1–6].
2.Use ofNovelAgents
The availability of novel agents has expanded treatment
options and has improved outcomes of myeloma patients.
A number of phase III clinical trials have demonstrated the
eﬃcacy of novel agent combinations and their superiority
to VAD (vincristine, doxorubicin, and dexamethasone) regi-
men [7, 8]. Some novel agents appear to be active in high-
risk patients, for example, those with adverse cytogenetics
andmolecularmarkersorcertaincomorbiditiessuchasrenal
failure. Characterization of molecular events at cellular and
marrow microenvironment levels has provided a platform
for the development of various novel drugs in MM includ-
ing proteasome inhibitors, immunomodulatory drugs, and
HDAC (histone deacetylase) inhibitors [7, 8].
Bortezomib (velcade), the ﬁrst-in-class proteasome
inhibitor, was initially approved for the treatment of2 Bone Marrow Research
relapsed/refractory MM as a single agent [9, 10]. However,
the great beneﬁcial role it had exhibited in several clinical
studies allowed the expansion of its role to become not only
an integral part of induction therapy for newly diagnosed
MM, but also a valuable element of consolidation and
maintenancetherapiesinthepre-andposttransplantsettings
[9–15]. Bortezomib and dexamethasone combination has
become an important part of standard induction therapy
for newly diagnosed myeloma. This combination can be
given twice or once weekly. The once-weekly schedule has
proven to be equally eﬀective and safer than the twice-weekly
regimen speciﬁcally for patients more than 65 years of age.
Bortezomib can also be safely given in various combinations
with other agents including melphalan, cyclophosphamide,
thalidomide, doxorubicin, and lenalidomide [7, 9, 11, 13–
16]. Despite its safety proﬁle, which allowed use in patients
with renal failure and elderly individuals, the following
adverse events have been reported: peripheral neuropa-
thy, extramedullary plasmacytomas, gastrointestinal upset,
myelotoxicity, and severe pulmonary complications [9, 12,
13, 15–17].
3. Autologous Stem CellTransplantation
Since the mid-1990s, high-dose chemotherapy followed by
autologous hematopoietic stem cell transplantation (auto-
HSCT) has been considered the standard of care for
frontline therapy in MM patients who are eligible for
transplantation [18]. The choice of induction therapy has
moved from conventional chemotherapy, for example VAD
protocol, to newer regimens that incorporate novel agents
likethalidomide,lenalidomide,andbortezomib.Upfrontuse
of these agents, with 3-drug combinations in particular, has
produced unprecedented rates of complete response (CR)
that were never seen with old conventional chemother-
apy and subsequent auto-HSCT [19]. Auto-HSCT oﬀered
after novel-agent-based induction therapies provides further
improvement in the depth of response which is translated
into longer progression-free survival, and potentially overall
survival [18, 19]. Therefore, novel agents and auto-HSCT
are complementary therapeutic strategies in patients with
MM [19]. Improving the outcomes of HSCT in the future
will require the exploration of novel strategies aimed at
addressing the following issues: reduction of morbidity
attributed to high-dose therapy, improving the eﬃcacy of
conditioning therapies, and the use of novel agents in the
post-HSCT period [20].
For transplant-eligible patients, a bortezomib-based
induction therapy is associated with improved disease
control after HSCT and should, therefore, be considered
the standard of care [20]. Moreover, a number of studies
incorporating bortezomib as part of induction therapy have
shown no adverse impact of bortezomib therapy on the
yield of stem cell harvest and engraftment in patients
with MM proceeding to transplant [21]. Auto-HSCT is
safe and eﬀective, but the outcome is independent of age,
time from diagnosis, previous treatment, and conditioning
therapy. However, achievement of CR and low international
prognostic index at transplant is essential prognostically
[22,23].HighCD34+stemcelldosecorrelateswellwithearly
hematopoietic reconstitution and improvement of overall
survival [22, 24]. Auto-HSCT for patients with MM can be
entirely performed at the outpatient department in cancer
centers that are fully equipped and can handle any evolving
crisis or emergency. Outpatient auto-HSCT can result in
shorter hospital stays and low transplant-related mortality
andcosts[25].Studieshavealsoshownthattheuseofcertain
conditioning therapies for HSCT can result in signiﬁcant
reductionorevenabolitionoftransfusionofbloodproducts,
for example, packed red cells and platelets [26].
4. Stem Cell Mobilization
Mobilization of stem cells prior to stem cell collection and
auto-HSCT in patients with MM is generally composed
of 2 parts: the ﬁrst part comprises the use of certain
chemotherapeutic agents that include a single agent like
cyclophosphamide or multiple agents in various combi-
nations, with diﬀerent dose schedules such as VAD, CD
(cyclophosphamide and dexamethasone), CAD (cyclophos-
phamide,adriamycin,anddexamethasone),IVE(ifosfamide,
etoposide, and epirubicin), EDAP (etoposide, dexametha-
sone,cytosinearabinoside,andcisplatin),CDVP(cyclophos-
phamide, doxorubicin, vincristine and prednisone), and
VTD-PACE (bortezomib, thalidomide, dexamethasone, cis-
platin, doxorubicin, cyclophosphamide, and etoposide), and
the second part is composed of administration of growth
factors such as granulocyte colony-stimulating factor (ﬁl-
grastim; G-CSF), pegylated G-CSF, and plerixafor (Mozobil)
in case of poor mobilization [27–40]. Various dose schedules
were used in both single- or multiple-agent chemothera-
peutic protocols, for example, doses of cyclophosphamide
r a n g e df r o m1 . 0t o7 . 0g r a m / m 2 [34–38, 40–42]. However,
recent studies have shown that adequate numbers of periph-
eral blood stem cells can be collected using growth factors
alone, without prior chemotherapy, and that the use of
cyclophosphamide for stem cell mobilization can overcome
the suppressive eﬀect of drugs, used in the treatment of MM,
like lenalidomide on stem cell collection [41, 42].
Although ﬁlgrastim can be used alone for stem cell
mobilization, studies have shown that the yield of stem cells
was higher in patients mobilized with cyclophosphamide
and G-CSF rather than with G-CSF alone, and that under
certain circumstances, some regimens may be preferred to
others, for example, VAD chemotherapy protocol followed
by standard doses of G-CSF has been shown to be as eﬀective
as high-dose cyclophosphamide, in addition to being less
toxic and allowing outpatient management with reduced
cost [28, 31, 34, 35, 41, 42]. G-CSF and pegylated G-CSF
may cause severe pain syndromes, and splenic rupture and
may even precipitate veno-occlusive crises in patients with
sickle cell anemia. However, in patients with sickle cell trait,
stem cell mobilization using G-CSF is generally safe. Due to
concerns of more serious adverse eﬀects of G-CSF in patients
withsicklecelltrait,closemonitoringofsuchpatientsshould
be maintained [43–47]. Plerixafor, a novel CXCR4 inhibitor,
is eﬀective in mobilization of peripheral blood stem cells
in myeloma patients who fail conventional mobilizationBone Marrow Research 3
techniques. It has shown good tolerance and high success
rates in patients who are labeled as poor mobilizers [29, 30,
32, 33].
5.StemCellCollection
Once the CD34+ cell count in peripheral blood exceeds
10.0 to 20.0 × 106/kg body weight, stem cell collection
by leukapheresis is usually commenced. Most transplant
centers make plans to obtain a target of 3.0 to 4.0 × 106
CD34+ cells/kg in case a single auto-HSCT is desired and
at a r g e to f6 . 0t o8 . 0× 106 CD34+ cells/kg in case a
tandem transplant is planned [48–50]. The optimal count
of CD34+ cells necessary for hematologic reconstitution is
not well characterized, but the minimal count of 2.0 to
3.0 × 106 CD34+ cells/kg is generally accepted as the limit
required to ensure short- as well as long-term hematologic
reconstitution in the majority of patients [31, 40, 42, 48–50].
The yield of stem cell collection depends on a number of
factors including age and performance status of the patient,
presenceofcomorbidities,thepreviouslinesoftherapygiven
to the patient, the bone marrow reserve, upfront versus
delayed auto-HSCT, the mobilization protocol used, and the
technology applied in stem cell collection [42, 49].
6. Cryopreservation of Stem Cells
Cryopreservation of hematopoietic stem cells (HSCs) is
routinely employed in auto-HSCT setting and is critical
for cord blood transplantation. A variety of cryopreserva-
tives have been used with diﬀerent freezing and thawing
techniques used in various transplantation centers. The
standard and the most commonly used cryopreservative is
DMSO (dimethylsulfoxide) which prevents freezing damage
to living cells. DMSO is usually used at concentrations of
10% combined with normal saline and serum albumin. It
is generally safe and nontoxic, but clinically it is associated
with signiﬁcant side eﬀects that include nausea, vomiting,
and abdominal cramps in addition to cardiovascular, neu-
rological, respiratory, renal, hepatic, and hemolytic adverse
eﬀects. Standardization of stem cell processing using cry-
opreservation or mechanical freezing is of vital importance
[51–53]. After cryopreservation and thawing of stem cells,
a signiﬁcant proportion of collected stem cells (20–30%)
becomes nonviable due to early irreversible apoptosis.
Therefore, systemic control for the viability of CD34+ cells
immediately before reinfusion is recommended [54].
7. Autologous Transplantation
without Cryopreservation
Studies have shown that peripheral blood stem cells (PBSCs)
can be stored safely at 4◦C for at least 5 days, while the
patient receives high-dose chemotherapy. Viability of stem
cells decreases progressively from day 5 onwards [55]. Liquid
storage of harvested HSCs, either at room temperature
or in standard blood refrigerators, is an alternative to
cryopreservation. Preclinical data supporting the use of non-
cryopreservedHSCsareavailablesince1957.Studiesonmice
reportedsuccessfulrescueafteradministrationoflethaldoses
of total body irradiation and reinfusion of bone marrow
cells that had been stored for 11 days at 25◦C. Subsequent
in vitro and clinical studies on humans showed that bone
marrow cells can be preserved in liquid state for 2 to 9
days without signiﬁcant loss of granulocyte/macrophage-
committed progenitor cells providing hematologic reconsti-
tution to patients receiving myeloablative therapy [56]. The
technique may be of value in 2 scenarios: (1) use in medical
institutions from areas with limited economic resources, that
is, having infrastructure to treat hematologic malignancies
but not cryopreservation facilities and (2) use in medical
institutions treating hematologic malignancies and in the
processofestablishinganHSCTprogramthatwilleventually
have cryopreservation capabilities [56–59].
The use of noncryopreserved stem cells in transplanta-
tion has the following advantages: (1) simplicity of imple-
mentation and allowing auto-HSCT to be done entirely as
outpatient, (2) reduction of transplant costs, (3) expansion
of the number of medical institutions that oﬀer stem cell
therapy, (4) prevention of DMSO toxicity, (5) saving time
between the last induction therapy and high-dose therapy,
and (6) no signiﬁcant reduction in viability of collected stem
cellsprovidedinfusionisdonewithin5daysofcollection.On
the other hand, noncryopreserved HSCT has the following
disadvantages: (1) limitation of the use of standard high-
dose schedules employed in auto-HSCT, (2) plenty of
coordination between various teams is required regarding
timing of stem cell mobilization, apheresis, administration
of high-dose therapy, and stem cell transfusion, and (3)
inability to store part of the collection and reserving it for
second transplant or other purposes in case a rich product is
obtained [56–62].
Melphalan, which is the standard chemotherapeutic
agent used in conditioning therapy prior to auto-HSCT
in MM, becomes undetectable in plasma and urine 1 and
6 hours, respectively, following intravenous infusion of a
high dose. Noncryopreserved stem cells can be reinfused
as early as 8 hours after high-dose melphalan. Stem cell
transfusion 8 to 24 hours following IV administration
of melphalan has been reported to be associated with
successful grafts. The dose of melphalan can range between
140 and 220mg/m2 [56, 59]. In a systemic review of the
published studies on noncryopreserved autologous PBSCT
in a variety of malignant hematological disorders including
MM, the following results were obtained: (1) median time
to neutrophil recovery ranged between 9 and 14 days, (2)
median time to platelet recovery ranged between 13.5 and 25
days, and (3) hematopoietic reconstitution was universal in
all the studies that included 560 patients. Only 1 graft failure
was reported, and it was attributed to an inadequate stem
cell dose [56]. Other studies reported neutrophil recovery as
late as 27 days and platelet recovery as late as 37 days [57].
Treatment-related mortality was reported to range from 0.0
to 13.0%. The deaths reported were due to infections, heart
failure, interstitial pneumonitis, and hepatic veno-occlusive
disease [56–59, 61]. As stem cells can be stored without4 Bone Marrow Research
cryopreservation for a limited period of time, conditioning
therapies for malignant hematological disorders that require
administrationover6daysormoreshouldeitherbeexcluded
ortheseconditioning therapiesshouldbechangedaltogether
to be administered over 1 to 3 days. The rule of the sooner
the better should therefore be applied so that harvested stem
cells should be reinfused within 5 days of collection [56].
Studies comparing overnight storage of autologous stem
cell apheresis products at 4◦C with immediately cryopre-
served products showed no statistically signiﬁcant diﬀerence
between the two groups regarding viability of collected stem
cells, neutrophil and platelet engraftment days, safety, and
even long-term outcome of the primary disease. Additional
beneﬁts of overnight storage of harvested products were
reduction in costs and processing time [63–65].
8. Simpliﬁed CryopreservationTechniques
Simpliﬁed methods of cryopreservation, that is, storage
of harvested stem cells in mechanical freezers at −80◦C
using cryoprotective solutions that contain DMSO, have
been successfully utilized in various parts of the world.
Results of these simpliﬁed and less expensive cryopreser-
vation procedures with regard to hematopoietic recovery
after myeloablative therapy are comparable to standard
cryopreservation techniques [66–70]. For short-term (less
than 168 hours) storage of stem cells, the use of a storage
medium composed of combination of super cooling, and
University of Wisconsin solution was successfully used.
Preservation of stem cells beyond 168 hours was associated
with reduced viability of stored stem cells [71].
9. Tandem Transplantation in Myeloma
In selected subgroups of patients, tandem or second trans-
p l a n t sm a yb em o r ee ﬀective than single rounds of high-dose
therapy and auto-HSCT. The timely application of a tandem
transplant has extended event-free and overall survival
independent of the cytogenetics and beta-2-microglobulin
in some patients [72]. In most instances, a second auto-
HSCT is performed using cryopreserved stem cells collected
prior to the ﬁrst auto-HSCT [49]. The indications for a
tandem transplant in myeloma patients include relapse after
ﬁrst auto-HSCT or following prolonged remission and not
achieving CR or near CR with the ﬁrst auto-HSCT. However,
in patients who are in CR or near CR, the second auto-HSCT
could be performed as a salvage therapy in the future rather
than an elective tandem procedure [49, 50, 72, 73].
10. Engraftment Syndrome and/or
Autologous GVHD
During neutrophilic recovery following HSCT, a constel-
lation of clinical manifestations that include fever, erythe-
matous skin rash, nausea, vomiting, diarrhea, and noncar-
diogenic pulmonary edema may occur [74]. These clinical
features are usually referred to as engraftment syndrome
which may be a manifestation of graft versus host reaction.
This syndrome reﬂects cellular and cytokine interactions
and may be associated with signiﬁcant transplant-related
mortality and morbidity due to pulmonary leak syndrome
a n dm u l t i o r g a nf a i l u r e[ 74–77]. It has been well reported in
autologous HSCT setting, and the extreme form is usually
referred to as an autologous form of graft versus host disease
(GVHD). The predisposing factors for auto-GVHD include
MM as the primary disease, second auto-HSCT, heavily pre-
treated patients, high CD34+ cells infused, and achievement
ofhighlevelsofabsolutelymphocytecountsafterHSCT[74–
79]. Early recognition of this syndrome is vital in order to
administer appropriate GVHD therapy which includes high-
dose corticosteroids, alemtuzumab, inﬂiximab, daclizumab,
and etanercept [74–78].
11. Conclusion
Auto-HSCT without cryopreservation is feasible and can be
performed successfully in cancer centers that have speciﬁc
skills as well as standardized CD34+ cytometry technique in
order to obtain accurate counting of progenitor cells but lack
or are in the process of having cryopreservation facilities. It
is simple, safe, and cost-eﬀective. However, proper planning
and coordination between various teams is vital for eﬃcient
mobilization and collection of hematopoietic progenitor
cells, administration of the high-dose chemotherapy, and
infusion of fresh stem cell products in a timely manner for
optimal transplant outcome.
Managing teams should cautiously use ﬁlgrastim in
patients with sickle cell disorders and should take into
consideration the possible evolution of an engraftment
syndrome after a successful autograft.
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